A Predictive Model for Initial Platinum-Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue-Derived Small Extracellular Vesicles

Quick Facts

  • Publication title: A Predictive Model for Initial Platinum-Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue-Derived Small Extracellular Vesicles
  • Journal: J Extracell Vesicles
  • Year: 2024
  • DOI: 10.1002/jev2.12486
  • PMID/PMCID: 39104279; PMC11300955

Research overview

In this study, 4D data-independent acquisition (DIA) proteomic sequencing was performed on tsEVs obtained from 58 platinum-sensitive and 30 platinum-resistant patients with EOC. Thus, this model could predict the efficacy of initial platinum-based chemotherapy in patients with EOC post-surgery, providing prognostic insights even before the initiation of chemotherapy.

Key findings

Epithelial ovarian cancer (EOC) is an often-fatal malignancy marked by the development of resistance to platinum-based chemotherapy.

Thus, accurate prediction of platinum drug efficacy is crucial for strategically selecting postoperative interventions to mitigate the risks associated with suboptimal therapeutic outcomes and adverse effects.

Tissue-derived extracellular vesicles (tsEVs), in contrast to their plasma counterparts, have emerged as a powerful tool for examining distinctive attributes of EOC tissues.

In this study, 4D data-independent acquisition (DIA) proteomic sequencing was performed on tsEVs obtained from 58 platinum-sensitive and 30 platinum-resistant patients with EOC.

Echo Biotech Role

Echo Biotech contributed EV isolation and purification, EV characterization, EV proteomics.

Related platforms: Exoomics®

Related services and capabilities: Biofluid EV Isolation & Purification, Tissue EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV Proteomics

References

Original publication: A Predictive Model for Initial Platinum-Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue-Derived Small Extracellular Vesicles Journal of Extracellular Vesicles. 2024. DOI: 10.1002/jev2.12486. PMID/PMCID: 39104279; PMC11300955.